Atlas Trials

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Clinical trial NCT05586841 · COMPLETED

Trial details

NCT number
NCT05586841
Sponsor
Beijing 302 Hospital
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HR+/HER2- Advanced Breast Cancer
Start date
2022-10-01
Primary completion
2025-12-30
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.